Helicobacter

Papers
(The H4-Index of Helicobacter is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
A real‐world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy o70
Gastric Helicobacter pylori infection does not contribute to extraoral halitosis and its eradication cannot achieve substantial reduction of halitosis56
Issue Information51
UreBimmunodominant epitope‐specificCD8+T‐cell responses were beneficial in reducing gastric symptoms inHelicobacter pylori‐infected individuals43
A “new” option in Helicobacter pylori eradication: High‐dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting43
Second‐ and Third‐Line Therapies for Helicobacter pylori Eradication in Slovenia: Data From 2013–2023 of the European Registry on 42
Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta‐analysis of RCTs41
Proteomic Profiling of Extracellular Vesicles Reveals Potential Biomarkers for Helicobacter pylori Infection and Gastric Cancer41
DNA starvation/stationary phase protection protein of Helicobacter pylori as a potential immunodominant antigen for infection detection37
Tegoprazan‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China37
Low‐dose or high‐dose amoxicillin in vonoprazan‐based dual therapy for Helicobacter pylori eradication? A systematic review and meta‐analysis36
Expansion of cagA Copy Number in Helicobacter pylori During Co‐Infection in a Mouse Model36
Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp‐EuReg)35
Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis35
33
Issue Information32
Seroprevalence of Helicobacter pylori infection among schoolchildren in southern Taiwan—A 20‐year longitudinal follow‐up32
Nationwide survey ofHelicobacter pyloriseropositivity and gastric atrophy in Zambia31
Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicro30
Roles of Gastric Non‐Helicobacter pylori Helicobacter Species in Gastric Disease Development: A Review30
Letter to the Editor regarding the article: “Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy”29
Droplet Digital PCR ‐Based Detection of Clarithromycin Resistance on Rapid Urease Test Samples Predicts 29
Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines26
Low compliance to post‐screening recommendations in a family‐based Helicobacter pylori screening and treatment program: A prospective cohort study26
Managing Helicobacter pylori as an Infectious Disease: Implementation of Antimicrobial Stewardship25
0.082669973373413